Диссертация (1140195), страница 14
Текст из файла (страница 14)
Cairns, M. Gent, J. Singer. // N Engl J Med. –1985. – Vol. 313. – P. 1369.31. CAPRIE Steering Committee – a randomized, blinded trial of clopidogrel versusaspirin in patients at risk of ischemic events (CAPRIE) // Lancet. - 1996. - Vol.348. - P. 1329 – 1339.32. Chen, Z. Addition of clopidogrel to aspirin in 45 852 patients with acutemyocardial infarction: randomized placebo-controlled trial / Z. Chen, L. Jiang,Y. Chen // Lancet.
- 2005. - Vol. 366. - P. 1607 – 1621.33. Clopidogrel resistance is associated with increased risk if recurrent events inpatients with acute myocardial infarction / S. Matetzky, B. Shenkman V. Guettaet al. // Circulation. - 2004. - Vol. 109. - P. 3171 – 3175.34. Comparison of ticagrelor with clopidogrel in patients with a planned invasivestrategy for acute coronary syndromes (PLATO): a randomized double-blind121study / C.P. Cannon, R.A. Harrington, S. James et al. // Lancet.
– 2010. - Vol.375 (9711). – P. 283 - 293.35. Contribution of gene sequence variation of the hepatic cytochrome P-450 3A4enzyme to variability in individual responsiveness to clopidogrel / DJ.Angiolillo, A. Fernandez-Ortiz, E. Bernardo, et al. // Arterioscler. Thromb. Vasc.Biol. - 2006.
- Vol. 26. - P. 1895 – 1900.36. Cuisset, T. High post-treatment platelet reactivity identify low-responders todual antiplatelet therapy at increased risk of recurrent cardiovascular events afterstenting for acute coronary syndrome / T. Cuisset, C. Frere, O. Quilici // Thromb.Haemost. - 2006. - Vol. 4. - P. 542 – 549.37.
CURE Investigators. Effects of pretreatment with clopidogrel and aspirinfollowed by long-term therapy in patients undergoing percutaneous coronaryintervention: the PCI-CURE study / S. Mehta, S. Yusuf, R. Peters et al. // Lancet.- 2001. - Vol. 358, № 9281. - P. 527 – 533.38. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-doseclopidogrel and high-dose versus low-dose aspirin in individuals undergoingpercutaneous coronary intervention for acute coronary syndromes (CURRENTOASIS 7): a randomized factorial trial / S.R.
Mehta, J.F. Tanguay, J.W.Eikelboom et al // Lancet. – 2010. – Vol. 376, № 9748. – P. 1233 -1243.39. Cytochrome P450 genetic polymorphisms and the response to prasugrel:relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes / J.L.Mega, S.L. Close, S.D. Wiviott et al. // Circulation. - 2009.
– Vol. 119, № 19. P. 2553 - 2560.40. Daemen, J. Drug-eluting stent update 2007: part II: Unsettled issues / J.Daemen, P. Serruys // Circulation. - 2007. - Vol. 116, № 8. - P. 961 – 968.41. De La Cruz, J.P. Efects of the selective inhibition of platelet thromboxanesynthesis on the platelet-subendothelium interaction / J.P. De La Cruz, M.A.Villalobos, R. Escalante // British Journal of Pharmacology.
– 2002. Vol. 137. –P. 1082 - 1088.12242. Dhatariya, K. Aspirin for everyone over 50? Do not forget aspirin resistance / K.Dhatariya // BMJ. - 2005. - Vol. 331, № 7509. - P. 161.43. Effect of a high loading dose of clopidogrel on platelet function in patientsundergoing coronary stent placement / I. Müller, M. Seyfarth, S. Rudiger, et al.// Heart. - 2001. - Vol. 85, № 1. - P.
92 – 93.44. European Guidelines on cardiovascular disease in clinical practice (version2012): the Fifth Joint Task Force of the European Society of Cardiology andOther Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of nine societies and by invited experts)[Электронный ресурс] – Режим доступа: http://www.ncbi.nlm.nih.gov/pubmed/22763626.45. Fang Y.
Association of Rs10487667 genetic polymorphism of thromboxanesynthase with myocardial infarction in Uigur population of Xinjiang / Yu Fang,Yi Xue, Za Zhi // Heart. - 2010 Nov. – Vol. 44, № 11. – P. 1032 - 1036.46. Ferguson, A. Aspirin and Clopidogrel Response Variability / A. Ferguson //Tex. Heart Inst. J.
– 2008. – Vol. 35, № 3. – P. 313–320.47. Gabriel Steg, Ph. Acute Myocardial Infarction in patients presenting with STsegment elevation (Management of). European Society of Cardiology[Электронный ресурс] / Ph. Gabriel Steg, K. James Stefan – Режим доступа:http://www.escardio.org/GUIDELINES-SURVEYS/ESC-GUIDELINES/Pages/acs-st-segment-elevation.aspx.48. Genetic determinants of response to clopidogrel and cardiovascular events / T.Simon, C. Verstuyft, M.
Mary-Krause et al. // N. Engl. J. Med. - 2009. - Vol.360. - P. 363 – 375.49. Gladding, P. The Pharmacogenetics and Pharmacodynamics of ClopidogrelResponse: An Analysis From the PRINC (Plavix Response in CoronaryIntervention) Trial / Patrick Gladding, Mark Webster, Irene Zeng // J. Am. Coll.Cardiol. Intv. – 2008. - № 1. – P. 620 - 627.12350.
Gregory, G.P. The CURE trial: using clopidogrel in acute coronary syndromeswithout ST segment elevation / G.P. Gregory, D.L. Bhatt // Cleveland ClinicJournal of Medicine. – 2002. – Vol. 69. – P. 377 - 385.51. Gurbel, P.A. Clopidogrel resistance? / P.A. Gurbel, U.S. Tantry // Thromb.Research. - 2007. - Vol. 120. - P. 311 – 321.52. Gurbel, P. Clopidogrel for coronary stenting: response variability, drugresistance, and the effect of pretreatment platelet reactivity / P. Gurbel, K.Bliden, B. Hiatt // Circulation.
- 2003. - Vol. 107, № 23. - P. 2908 - 2913.53. Gurbel, P. Durability of platelet inhibition by clopidogrel / P. Gurbel, K. Bliden// Am. J. Cardiol. - 2003. - Vol. 91, № 9. - P. 1123 - 1125.54. Gurbel, P. Failure of clopidogrel to reduce platelet reactivity and activationfollowing standard dosing in elective stenting: implication for thrombotic eventsand restenosis / P. Gurbel, W. Samara, K.
Bliden // Platelets. - 2004. - Vol. 15,№ 2. - P. 95 – 99.55. Hankey, G.L. Aspirin resistance / G.L. Hankey, J. Eikelboom // Lancet. - 2006.- Vol. 367. - P. 606 – 617.56. Impact ofPglycoprotein on clopidogrel absorption / D. Taubert, N. VonBeckerach, G. Grimberg, et al. // Clin. Pharmacol. Ther. - 2006. - Vol. 80. - P.486 – 501.57.
Influence of aspirin resistance on platelet function profiles in patients on longterm aspirin and clopidogrel after percutaneous coronary intervention / DJ.Angiolillo, A. Fernandez-Ortiz, E. Bernardo, et al. // Am. J. Cardiol. - 2006. Vol. 97, № 1. - P. 38 – 43.58. Interindividual variability in the response to oral antiplatelet drugs: a positionpaper of Working Group on antiplatelet drugs resistanse appointed by theSection of Cardiovascular Interventions of the Polish Cardiac Society, endorsedby the Working Group on Thrombosis of the European Society of Cardiology /W.
Kuliczkowski, A. Witkowski, L. Polonski, et al. // European Heart Journal. 2009. - Vol. 30. – P. 426 - 435.12459. ISIS – 2 (Second international Study of Infarct survival) collaborative Group.Randomized trial of intravenous streptokinase, oral aspirin, both or neitheramong 17187 cases of suspected acute myocardial infarction: ISIS -2 // Lancet. –1988.
- № 2. – P. 349 - 360.60. Jack, D. A significant drug-metabolizing role for CYP3A5? / D. Jack et al. //Drug Metabolizm & Disposition. - 2003. - Vol. 31, № 12. - P. 1526 – 1530.61. Jarvis, G.E. Platelet aggregation: turbidimetric measurements / G.E. Jarvis //Methods Mol. Biol. – 2004. - Vol. 272. - P.
65 – 76.62. Kamala, Bhavaraju. Antagonism of P2Y12 reduces physiological thromboxanelevels / Kamala Bhavaraju, Alexander Georgakis, Jianguo Jin // Platelets. – 2010.– Vol. 21, № 8. – P. 604-609.63. Kim, S.H. Association of thromboxane A2 receptor gene polymorphism with thephenotype of acetyl salicylic acid-intolerant asthma / S.H. Kim, J.H. Choiw, H.S.Park // Clin. Exp.
Allergy. - 2005. - Vol. 35. - P. 585–590.64. Lau, W. Atorvastatin reduces the ability of clopidogrel to inhibit plateletaggregation: a new drug-drug interaction / W. Lau, L. Waskell, P. Watkins //Circulation. - 2003. - Vol. 107, № 1. - P. 32 - 37.65. Lepantalo, A. Limited early antiplatelet effect of 300 mg clopidogrel in patientswith aspirin therapy undergoing percutaneous coronary interventions / A.Lepantalo, K. Virtanen, J.
Heikkil // Eur. Heart J. – 2004. – Vol. 25. – P. 476 –483.66. Libby, P. From vulnerable plaque to vulnerable patient: a call for newdefinitions and risk strategies assessment / Peter Libby et al. // Part I. Circulation.– 2003. – Vol. 108. – P. 1664 - 1672.67. Long-term endothelial dysfunction after coronary artery stenting / P. Caramori,V. Lima, P. Seidelin et al.
// JACC. - 1999. - Vol. 34, № 6. - P. 1675 – 1679.68. Matetzky, S. The genetic basis of platelet responsiveness to clopidogrel / S.Matetzky, P. Fefer // Thromb. Haemost. - 2011. - Vol. 106. - P. 203 – 210.12569.McNicol, A. Platelets and anti-platelet therapy / A. McNicol, S.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
